Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | NR2E3 | Q9Y5X4 | 2/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.32 |
| ▸ | AMPD1 | P23109 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965402 | 0.86 | TDP1 (0.59) | TDP1PPARGNR2E3NCOR2MAPT | |
| SCHEMBL18501101 | 0.85 | TDP1 (0.44) | TDP1PPARGNR2E3NCOR2MAPT | |
| SCHEMBL16471803 | 0.85 | — | — | |
| SCHEMBL19751691 | 0.85 | TDP1 (0.39) | TDP1PPARGNR2E3NCOR2L3MBTL1 | |
| SCHEMBL21514073 | 0.85 | GAA (0.33) | GAA | |
| SCHEMBL4970357 | 0.85 | TDP1 (0.39) | TDP1PPARGNR2E3NCOR2L3MBTL1 | |
| SCHEMBL4964756 | 0.82 | TDP1 (0.31) | TDP1 | |
| SCHEMBL19751731 | 0.82 | TDP1 (0.31) | TDP1 | |
| SCHEMBL19751621 | 0.82 | TDP1 (0.31) | TDP1 | |
| SCHEMBL4962526 | 0.78 | TDP1 (0.50) | TDP1PPARGNR2E3NCOR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731982-B2 | Biotin derivatives | Life Technologies Corporation | 2023-08-22 | — | — | US | disclosed |
| US-11731982-B2 | Biotin derivatives | Life Technologies Corporation | 2023-08-22 | — | — | US | disclosed |
| US-20190322681-A1 | Biotin Derivatives | LIFE TECHNOLOGIES AS (NO) | 2019-10-24 | — | — | US | disclosed |
| EP-2633062-B1 | BIOTIN DERIVATIVES | LIFE TECHNOLOGIES CORP (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20170174700-A1 | Biotin Derivatives | Life Technologies Corporation | 2017-06-22 | — | — | US | disclosed |
| US-20170174700-A1 | Biotin Derivatives | Life Technologies Corporation | 2017-06-22 | — | — | US | disclosed |
| US-9567346-B2 | Biotin derivatives | Life Technologies Corporation (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567346-B2 | Biotin derivatives | Life Technologies Corporation (US) | 2017-02-14 | — | — | US | disclosed |
| US-20140011255-A1 | Biotin Derivatives | Life Technologies Corporation (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011255-A1 | Biotin Derivatives | Life Technologies Corporation (US) | 2014-01-09 | — | — | US | disclosed |
| WO-2012058635-A1 | BIOTIN DERIVATIVES | Life Technologies Corporation (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731982-B2 | Biotin derivatives | BTD, HLCS, BRI3BP | TDP1 4350/4885PPARG 1919/4885NR2E3 2875/4885 |
| US-20140011255-A1 | Biotin Derivatives | BTD, HLCS, BRI3BP | TDP1 4350/4885PPARG 1919/4885NR2E3 2875/4885 |
| US-20190322681-A1 | Biotin Derivatives | BTD, HLCS, BRI3BP | TDP1 4350/4885PPARG 1919/4885NR2E3 2875/4885 |
| US-20170174700-A1 | Biotin Derivatives | BTD, HLCS, BRI3BP | TDP1 4350/4885PPARG 1919/4885NR2E3 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.